OverviewSuggest Edit

IsoRay Inc. is a national isotope-based medical company. With its patented radioisotope technology, the Company offers products including Cesium-131 seeds and other relevant treatment medicine for cancer and other malignant diseases. Its subsidiary, IsoRay Medical Inc., is the sole producer of Cesium-131 brachytherapy seeds. Brachytheraphy is when cancer-fighting medical radioisotopes are implanted in or around the affected tissue so to be as close to cancer as possible.

TypePublic
Founded1998
HQRichland, US
Websiteisoray.com

Latest Updates

Employees (est.) (Sept 2019)43(+14%)
Revenue (FY, 2019)$7.3 M(+24%)
Share Price (Jul 2020)$0.7 (-1%)
Cybersecurity ratingAMore

Key People/Management at Isoray

Lori A. Woods

Lori A. Woods

Chief Executive Officer & Member of the Board of Directors
Jonathan Hunt

Jonathan Hunt

Chief Financial Officer
Michael L. Krachon

Michael L. Krachon

Vice President of Sales and Marketing
Krista Cline

Krista Cline

Director of Operations, Corporate Secretary
William A. Cavanagh

William A. Cavanagh

Chief Research and Development Officer
Jennifer Streeter

Jennifer Streeter

Interim Chief Operating Officer & Vice President of Human Resources
Show more

Isoray Office Locations

Isoray has an office in Richland
Richland, US (HQ)
350 Hills St #106
Show all (1)

Isoray Financials and Metrics

Isoray Revenue

Embed Graph
View revenue for all periods
Isoray's revenue was reported to be $7.31 m in FY, 2019
USD

Revenue (Q3, 2020)

2.9m

Gross profit (Q3, 2020)

1.7m

Gross profit margin (Q3, 2020), %

59.2%

Net income (Q3, 2020)

(545.0k)

EBIT (Q3, 2020)

(548.0k)

Market capitalization (24-Jul-2020)

46.7m

Closing stock price (24-Jul-2020)

0.7

Cash (31-Mar-2020)

2.4m

EV

45.3m
Isoray's current market capitalization is $46.7 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

5.1m4.5m4.2m4.6m4.8m4.8m5.9m7.3m

Cost of goods sold

4.4m4.4m4.4m4.4m4.6m3.9m4.1m4.3m

Gross profit

703.2k150.2k(196.5k)167.4k129.2k838.0k1.8m3.0m

Gross profit Margin, %

14%3%(5%)4%3%18%31%42%
USDQ1, 2012

Financial Leverage

1.3 x
Show all financial metrics

Isoray Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Isoray Online and Social Media Presence

Embed Graph

Isoray News and Updates

Isoray To Announce Second Quarter Fiscal 2020 Financial Results on February 11, 2020

Conference Call is Tuesday, February 11, 2020 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, February 11, 2020 at 4:30 p.m. ET/1:30 p.m. PT

Isoray Announces Fourth Quarter and Full-Year Fiscal 2019 Financial Results

Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy

Isoray Announces Second Quarter Fiscal 2019 Financial Results

Record Revenue and Gross ProfitRevenue Increased 24% Year-Over-Year

Radiotherapy Market 2018 Trend and Key Players Analysis: Isoray, View Ray, Fuji Holdings, Philips Healthcare and Forecasts Up To 2023

Global Radiotherapy Market- by treatment type (X-rays, External beam radiotherapy, proton therapy and others), by application (Breast cancer, prostate cancer, lung cancer and others); - Forecast to 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Isoray Blogs

When is a change worth the trouble for brachytherapy?

Gains in engagement, conformal coverage, seamless logistics, planning, and procedural efficiency drive Wisconsin brachytherapy program’s transition to Cesium Blu™. The post When is a change worth the trouble for brachytherapy? appeared first on Isoray - Treating Prostate Cancer with Brachytherapy.

The Big Reason Why One Team Switched to Cesium Blu Brachytherapy

 “The potential to smooth out our workflow and increase our potential candidate pool for the procedure given the ability to do brachytherapy with Cesium Blu prior to EBRT is a compelling motivation for adding it to our prostate cancer treatment arsenal,”- Dr. Bobby Koneru first in Eastern Iowa using…

The fight to raise awareness and the patient-friendly nature of brachytherapy.

Welcome to the Isoray’s Prostate Cancer Connect Podcast! Each episode of the series, Dr. John Sylvester and featured guests will be talking in-depth about the current status and advancements in brachytherapy for prostate cancer treatment. How do we find the right awareness vehicle at the right time …

Isoray Announces Second Quarter Fiscal 2020 Financial Results

Revenue Increased 16% Year-Over-Year Gross Profit Increased 45% Year-Over-Year RICHLAND, WASHINGTON – February 11, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its …

Isoray Collaborates with MIM Software to Deliver an Advanced Treatment Solution for Recurrent Head and Neck Cancers

Bundled Treatment Program Provides New Opportunities For Treating Physicians and Patients Facing Limited Options RICHLAND, WASHINGTON – February 5, 2020 – Isoray, Inc. (NYSE American: ISR) today announced an executed agreement with MIM Software to deliver a novel one-stop-provides-all program to tre…

Episode 3: How brachytherapists are partnering with urologists and readying the next generation of practitioners.

While brachytherapy continues to demonstrate positive outcomes with swift side effect resolution for prostate cancer treatment, the modality remains underutilized. In this episode, Dr. John Sylvester is joined by radiation oncologist Dr. Alex Hsi to discuss why the use of brachytherapy is declining,…
Show more

Isoray Frequently Asked Questions

  • When was Isoray founded?

    Isoray was founded in 1998.

  • Who are Isoray key executives?

    Isoray's key executives are Lori A. Woods, Jonathan Hunt and Michael L. Krachon.

  • How many employees does Isoray have?

    Isoray has 43 employees.

  • What is Isoray revenue?

    Latest Isoray annual revenue is $7.3 m.

  • What is Isoray revenue per employee?

    Latest Isoray revenue per employee is $170.1 k.

  • Who are Isoray competitors?

    Competitors of Isoray include Nanospectra, Infogene and Vigilant Biosciences.

  • Where is Isoray headquarters?

    Isoray headquarters is located at 350 Hills St #106, Richland.

  • Where are Isoray offices?

    Isoray has an office in Richland.

  • How many offices does Isoray have?

    Isoray has 1 office.